In recent years, use of tirzepatide and other GLP-1 receptor agonists has surged beyond their approved clinical indications, particularly for weight loss driven by cosmetic reasons
Right now, it sits at the center of multiple strong market forces
Major payers including Aetna, Cigna, Elevance Health, Humana, UnitedHealthcare and Wellcare also released their MA offerings for 2025, as previously reported by Fierce Healthcare
In some patients, rapid GLP-1 signaling changes can overstimulate anxiety centers in the amygdala and trigger a hypervigilant state
Have severe or unstable medical conditions without close medical supervision
When taking any prescription medication, including Saxenda, it is essential to report new or unusual symptoms to your GP or healthcare provider promptly